IntroduCtIon
Psoriatic arthritis (PsA) is a heterogeneous disease which can manifest in several ways including arthritis, enthesitis, dactylitis, axial disease and skin/ nail involvement. The lack of a specific validated target for PsA means that the primary outcome measure used in recent interventional studies has been the American College of Rheumatology 20% improvement (ACR20) criteria, a measure originally developed for rheumatoid arthritis focusing on peripheral joint activity. 1 However, new composite targets encompassing the complex manifestations of PsA have been developed. These include the Psoriatic Arthritis Disease Activity Score (PASDAS) and the GRAPPA CompositE Index (GRACE), 2 and, in addition, the Composite Psoriatic Disease Activity Index (CPDAI). 3 In addition to measuring disease activity at any point in time, these indices can also serve as responder indices and cut-offs for response have been developed. 4 The TIght COntrol in Psoriatic Arthritis (TICOPA) study was the first study to demonstrate that tight control of disease utilising predefined activity levels to guide therapeutic changes resulted in significantly better clinical outcomes compared with standard care. 5 In the TICOPA study, the odds of achieving an ACR20 response at 48 weeks was twofold higher in the treat to target arm. However, the outcomes at intervening time points for each arm of the study were not described nor were validated composite disease activity measures for PsA reported. In this study, we evaluated treatment responses in the TICOPA study using the PASDAS, GRACE and CPDAI indices and compared their performance.
Methods
The primary results of the TICOPA study have already been published. 5 In brief this randomised, controlled, parallel group, open label, multicentre clinical trial recruited people with early (less than 2 years), treatment-naive PsA. The full trial protocol is also available. 6 The primary objective of the trial was to compare tight control (TC) with standard care (SC), using minimal disease activity 7 as the treatment target. Participants received either TC or SC for a period of 48 weeks. Participants randomised to TC were seen every 4 weeks by the study physician and treated according to a predefined treatment protocol. Participants randomised to the SC arm were treated in a general rheumatology outpatient clinic supervised by a consultant rheumatologist. These patients were generally reviewed every 12 weeks but were seen more often if clinically indicated, with no formal measures of disease activity used in clinical decision making. A blinded assessor collected clinical assessments and patient reported outcomes every 12 weeks, and the composite disease activity measures were derived from these. 
Composite measures Derived PASDAS
The PASDAS is a weighted index comprising assessments of joints, function, acute phase response and quality of life and patient and physician Visual Analogue Scores (VAS). It is given by the formula: Where LN = natural logarithm, PCS = Physical Component Summary Scale of 36-Item Short Form Health Survey (SF36), CRP=C reactive protein in mg/L. All VAS scores are 0-100 mm. Swollen joint count is 66 joints and tender joint count 68. In this study, the SF36 was not completed so an estimate of this outcome was calculated using the following formula: sf36pcs=51.615− (6.52×HAQ)−(1.529×BASDAI)−(0.429×PsAQoL) where: sf36pcs is the estimated physical component score of the SF36, HAQ is the Heath Assessment Score (range 0-3), 8 BASDAI is the Bath Ankylosing spondylitis Disease Activity Index (range 0-10) 9 and PsAQoL is the Psoriatic Arthritis Quality of Life measure. 10 This formula was obtained by regression analysis using the GRACE data set 2 and explained 71% of the variance in sf36pcs scores (R 2 adj=0.71). The score range of the PASDAS is 0-10, with worse disease activity represented by higher scores.
Modified GrACe index
The GRACE is a composite score comprising assessments of joints, skin, pain, function and health-related quality of life. Each domain is transformed into a 'desirability' scale and the items then combined arithmetically. 4 The variables transformed are: ► 68 tender joint counts ► 66 swollen joint counts ► HAQ ► Patient global assessment of disease activity by VAS ► Patient VAS for skin ► Patient VAS for joints ► Psoriasis area and severity index (PASI) ► PsAQoL
In the TICOPA study, a VAS for skin was not collected and this item was thus omitted from the scale. Omitting the VAS for skin does not affect the score range as the score reflects the arithmetic mean of the individual components.
The GRACE index has a score range of 0-10 with worse disease activity represented by higher scores.
Modified CPdAI
This index measures disease activity in five domains: peripheral joints, skin, enthesitis, dactylitis and spine. 3 Within each domain, severity was graded as 0 (none), 1 (mild), 2 (moderate) and 3 (severe), according to predefined cut-offs (indicated in online supplementary table S1).
In the TICOPA study, the Ankylosing Spondylitis Quality of Life index was not obtained so this was substituted by the PsAQoL (range 0-20) using the same cut-off of 6. In addition, the DLQI was estimated using the following equation:
This formula was obtained by regression analysis using the GRACE data set 2 and explained 35% of the variance in DLQI scores (R 2 adj=0.35).
stAtIstICAl AnAlysIs
All statistical analyses were carried out in SPSS V.21. Where necessary, missing component data were replaced by carrying forward the last available observation. Comparison between groups at 48 weeks was made using an analysis of covariance with baseline values as the covariate. In addition, treatment groups were compared by calculating the area under the curve (AUC) and comparing the area with independent t-tests. We performed these analyses for all participants and, in addition, for those with oligoarthritis. Using previously defined cut-offs, we examined the proportion of people in each arm of the trial achieving good, moderate or poor outcome for each composite measure at 48 weeks, 4 comparing these proportions with the χ 2 test. 
Clinical and epidemiological research results
The study population consisted of 206 patients randomly assigned to either the TC (n=101, 49.0%) or SC (n=105, 51.0%). The baseline demographics of participants was, for TC and SC respectively, median age 46 years (range 18, 81) and 45 years (range 19, 71), males 53% and 52% and median duration of disease 0.9 months (range 0, 21.4) and 0.7 months (range 0, 23.6). In TC, 89.1% (n=90) of patients completed treatment and follow-up to week 48 with a similar proportion in SC (n=92, 87.6%). Baseline composite scores differed, with the tight control having higher baseline scores. Mean scores for each measure at each major time point are given, along with the statistical analysis, in table 1. The baseline individual domain scores for each of the composite measures for the entire population are given in the online supplementary table S2. Analysis of covariance, adjusting for baseline data, for all available data demonstrated a highly significant difference for each of the composite measures. AUC analysis also showed significant differences between groups for PASDAS but not GRACE and CPDAI. The dynamics of change for each composite measure are illustrated in the figure 1. For all measures, there was separation between the groups at the first 'blinded' assessment point, with further divergence at subsequent time points. For information, the CPDAI is reported by domain at baseline and 48 weeks in the online supplementary table S3.
The data for patients with oligoarthritis at study entry are given in table 2. The baseline individual domain scores for the group with oligoarthritis are given in the online supplementary table S4. Although comparison of groups by analysis of covariance achieved significance, the statistics were smaller than those found for the entire cohort, and the mean values for each measure were reduced. Further, AUC analysis failed to show a difference between treatment arms for all of the measures tested but the number of participants for the analysis was small. Of note, the mean figures for each composite measure did not diverge until 24 weeks for this PsA subgroup.
The proportion of people achieving 'good', 'moderate' and 'poor' response at 48 weeks, for each measure, is given in table 3. For the PASDAS, 64.5% of people who achieved a 'good' response were in the TC arm, and 68.9% of those who achieved a 'poor' response were in the SC arm. The figures for the GRACE index were 63.6% and 66.3%, respectively, and for the CPDAI, 66.7% and 63.7%. For each measure, the difference in proportions was highly significant.
dIsCussIon
The TICOPA study was the first to show that a treat to target approach improved clinical outcomes for patients with early PsA. The primary outcome was the composite measure developed for rheumatoid arthritis clinical trials, the ACR20. However, secondary outcomes demonstrated benefits across both articular and skin domains, although not for dactylitis and enthesitis. The current study describes the treatment response in terms of disease activity using three validated composite disease activity measures, all of which assess disease activity across several domains. Early separation was seen between the treatment groups with significant differences at 48 weeks and significantly more patients in the TC arm achieving a good clinical outcome. However, it must be acknowledged that these three composite measures were not assessed in their entirety in the TICOPA study, and that adaptations had to be made for the scores to be obtained. If the required data had been available, it is possible that the measures would have behaved differently.
The early separation between treatment groups at 12 weeks was probably due to the more aggressive use of methotrexate. As reported in the original paper, subjects in the TC arm had rapid escalation of oral methotrexate to 25 mg weekly, and this was reflected in the numbers achieving that dose at 3 months (TC 82.2%; SC 7.6%). If the minimal disease activity target had not been reached at 12 weeks, sulfasalazine was added to methotrexate so that the continued and more pronounced separation of treatment groups between 12 and 24 weeks was partly attributable to this combination therapy. This is important as it would be advantageous to be able to predict who would respond to either methotrexate alone or combination conventional disease modifying therapy. Beyond 24 weeks, TC patients who continued to have active disease were eligible for biological therapy with tumour necrosis factor blockers and the further relative improvement seen in the TC arm beyond 24 months probably reflects this. In the subgroup of people with oligoarthritis, contrasting results were obtained. The composite scores were lower at baseline, as would be expected, but the early difference seen for the entire cohort was not seen for the oligoarthritis subgroup alone. This result may reflect the possibility that none of the composite measures is appropriate for assessing disease activity where joint counts are low. An alternative explanation is that there is a a lack of effect of methotrexate in patients with oligoarthritis. In this respect, it is worth noting that in the landmark methotrexate in psoriatic arthritis trial, better results were seen in the polyarticular subset of the disease. 11 More data are needed on the appropriate treatment strategy for this common subgroup of PsA.
At the time the TICOPA study was commenced, validated composite measures for psoriatic arthritis were unavailable so that not all appropriate outcomes were measured to allow calculation of the PASDAS, CPDAI and GRACE. However, we were able to make an allowance for the missing measures, either by estimating, using available measures or, in the case of the GRACE instrument, a modular measure, to omit the outcome (a skin VAS score). The effect of these modifications on the performance of the measures is difficult to assess: an independent data set in which all these variables are collected would inform this question. The new composite measures assess disease activity in domains other than the joints, and offer more responsiveness, together with larger effect sizes, in clinical trials. 12 In the future, it would be appropriate to use such measures as the primary outcome in clinical trials as it is likely that fewer patients will be needed to show a difference in treatment arms. The PASDAS is currently being used in this way. 13 Which of the composite measures performs best in this study? In the overall patient population, there is probably little to choose between them, although the statistics for the PASDAS exceed those for the GRACE and CPDAI. Similarly, the PASDAS outperforms the GRACE and CPDAI using AUC analysis. Similar contrasts are evident in the analysis of the oligoarthritis patients. Each of the measures differs in construction: the PASDAS uses a weighted formula, the GRACE a modular scheme with each domain using a 'desirability' scale and the CPDAI also using a modular scheme in which patients are categorised within domain. 2 Each of the measures covers a similar range of domains but the CPDAI is the only measure addressing the five major domains of joints, skin, enthesitis, dactylitis and spine. The relative performance of the measures may have been a function of the patients enrolled in the study-spinal involvement was not prominent nor was the skin component-and the measures may perform relatively differently in alternative patient populations. In terms of outcome, all three measures gave a similar result (table 3), but it is worth noting that the cut-offs for outcome are still preliminary, although they have demonstrated good ability to distinguish radiographic progression in an alternative data set. 14 In conclusion, the performance of several novel composite disease activity measures have been examined using data from the TICOPA trial. Each measure was able to distinguish between treatment arms, although all three showed diminished ability to distinguish treatment effect for patients with oligoarthritis. Further data are needed to guide the decision on selecting a preferred composite measure for use as the primary outcome in PsA clinical trials. 
